Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Gastrointestinal
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Roche to appeal against preliminary NICE no for Herceptin for metastatic gastric cancer
07 July 2010
Roche says it will appeal against preliminary draft guidance from the National Institute for health and Clinical Excellence (NICE) in England and Wales that declines to recommend Roche's HER2-targeted Herceptin (trastuzumab) for treating metastatic ...
Atlantic appoints ex-Ardana chief as new pharma CEO
06 July 2010
The UK firm Atlantic Healthcare has promoted its chief commercial officer, Dr Huw Jones , to CEO of its therapeutics division, Atlantic Pharmaceuticals. Dr Jones has a mixed history in the pharmaceutical sector, having succeeded Maureen ...
Lupin gets US FDA approval for famotidine suspension
02 July 2010
Lupin 's US subsidiary has received final US FDA approval of its ANDA for famotidine for oral suspension (40mg/5ml), a generic version of Merck & Co's H 2 -antagonist anti-ulcer product Pepcid for oral suspension. Pepcid is used for the short-term ...
Japan grants priority review to Eisai's eribulin
24 June 2010
Eisai 's anticancer drug eribulin has been granted priority review status in Japan for its lead indication of breast cancer. The microtubule-targeting molecule, an analogue of halichondrin B, was submitted at the end of March for the treatment of ...
Bazedoxifene among new approval recommendations in Japan
08 June 2010
Wyeth/ Pfizer 's Viviant (bazedoxifene) has been recommended for approval in Japan, for the treatment of postmenopausal osteoporosis. The once-daily selective oestrogen receptor modulator (SERM) was filed in late 2007, based on results from ...
 
Market Insight - Differentiation guiding firms through maze of hepatitis C drug development
22 January 2010
The therapeutic landscape in HCV treatment is at an inflection point – recent data from the first generation of protease inhibitors promise the dawn of a new standard of care. But do not expect to ...
Challenges and opportunities in the Philippine pharma market
08 January 2010
On the face of it, the Philippines should be an attractive market for multinational pharmaceutical companies. There is a well-established healthcare system that covers the majority of the population ...
2010 Scrip 100 - Innovate to accumulate
09 December 2009
Drug delivery specialists continue to push the boundaries of innovative science, with recent highlights including the emergence of a needle-free migraine treatment and advances in RNAi delivery, ...
 
Revaprazan set to drive Yuhan's expansion
05 February 2009
The South Korean pharmaceutical company Yuhan Corp is looking to expand sales of its novel acid pump antagonist revaprazan into overseas markets as part of an effort to take group revenues past the ...
 
Questions linger over US comparative effectiveness funding
24 February 2009
The economic stimulus bill signed into law by US President Barack Obama on February 17th provides a $1.1 billion bolus to government agencies for comparative effectiveness research on medical ...
Life under FDAAA: Four months of post-approval studies and REMS
01 August 2008
The FDA has not hesitated to use its new safety powers since they took effect on March 25th. A review of original and supplemental NDA and BLA approval letters on the FDA's website indicates that, ...
 
Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD
01 October 2008
Background: Alicaforsen (ISIS 2302), an antisense to intercellular adhesion molecule-1 (ICAM-1) (CD54), was designed to inhibit ICAM-1 expression. ICAM-1 seems to play a role in cell-mediated ...
Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues
01 September 2008
Crohn's disease and ulcerative colitis represent the most common forms of inflammatory bowel disease (IBD), clinical conditions affecting the small and/or large bowel. It is well known that IBD is an ...
Molecular diagnostics of primary biliary cirrhosis
01 June 2008
Background: Primary biliary cirrhosis (PBC) is an autoimmune liver disease of unknown etiology characterized by the presence of antimitochondrial antibodies (AMA) in 90 – 95% of patients. AMA are ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm